title: Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy.
abstract: BACKGROUND
  Acute renal failure, with or without massive proteinuria, is a rare idiosyncratic toxicity of interferon (IFN)-alpha therapy. The authors sought to review their experience with this toxicity as well as the world literature on the subject.
  
  
  METHODS
  The authors describe two patients with chronic myeloid leukemia treated with IFN-alpha following high dose chemotherapy who developed renal failure and proteinuria after 3 and 4 weeks of IFN-alpha therapy, respectively. Fifteen previously reported cases of renal failure and proteinuria associated with IFN-alpha therapy are also reviewed.
  
  
  RESULTS
  Renal biopsies performed on the authors' two patients revealed focal segmental glomerulosclerosis. However, the other reported patients with IFN-alpha-associated renal failure and massive proteinuria had an assortment of pathologic findings.
  
  
  CONCLUSIONS
  The specific renal pathology associated with proteinuria may be a consequence of the condition and not its cause; differences in renal pathology may be caused by other predisposing factors. Patients treated with IFN-alpha following high dose chemotherapy, with or without autologous transplantation, should be followed for the development of proteinuria and renal failure.
authors.affiliation: Division of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
authors.forename: M
authors.initials: M
authors.lastname: Shah
authors.forename: E H
authors.initials: EH
authors.lastname: Jenis
authors.forename: B K
authors.initials: BK
authors.lastname: Mookerjee
authors.forename: J R
authors.initials: JR
authors.lastname: Schriber
authors.forename: M R
authors.initials: MR
authors.lastname: Baer
authors.forename: G P
authors.initials: GP
authors.lastname: Herzig
authors.forename: M
authors.initials: M
authors.lastname: Wetzler
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005923:Glomerulosclerosis, Focal Segmental / Q000139:chemically induced* / Q000652:urine; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D016898:Interferon-alpha / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D011507:Proteinuria / Q000139:chemically induced*
chemical_list: D016898:Interferon-alpha; D003561:Cytarabine; D005047:Etoposide; D015255:Idarubicin